Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Mallinckrodt
McKesson
Colorcon
Baxter

Last Updated: October 2, 2022

CLINICAL TRIALS PROFILE FOR RINTATOLIMOD


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Clinical Trials for Rintatolimod

Trial ID Title Status Sponsor Phase Summary
NCT00035581 ↗ Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART Terminated AIM ImmunoTech Inc. Phase 2 This is an open-label, prospective, randomized, controlled study of the safety and efficacy including clinical, immunologic, and virologic assessments of adding Ampligen to "HAART" in HIV infected patients with CD4 counts >300 and HIV-1 plasma RNA >500 and <30,000 copies/ml (PCR).
NCT00035581 ↗ Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART Terminated Hemispherx Biopharma Phase 2 This is an open-label, prospective, randomized, controlled study of the safety and efficacy including clinical, immunologic, and virologic assessments of adding Ampligen to "HAART" in HIV infected patients with CD4 counts >300 and HIV-1 plasma RNA >500 and <30,000 copies/ml (PCR).
NCT00035893 ↗ The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART Completed AIM ImmunoTech Inc. Phase 2 This is an open-label, prospective, randomized, controlled study of the safety and efficacy including clinical, immunologic, and virologic assessments of adding Ampligen to a Strategic Therapeutic Intervention (STI) of HAART in patients with plasma HIV RNA < 50 copies/ml (PCR) and CD4 levels > 400.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Rintatolimod

Condition Name

Condition Name for
Intervention Trials
Estrogen Receptor Negative 2
Progesterone Receptor Negative 2
HER2/Neu Negative 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Breast Neoplasms 4
Colorectal Neoplasms 4
Neoplasms 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Rintatolimod

Trials by Country

Trials by Country for
Location Trials
United States 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
New York 8
Pennsylvania 6
New Jersey 2
Florida 2
District of Columbia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Rintatolimod

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 2 9
Phase 1/Phase 2 6
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 4
Not yet recruiting 4
Recruiting 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Rintatolimod

Sponsor Name

Sponsor Name for
Sponsor Trials
Roswell Park Cancer Institute 9
AIM ImmunoTech Inc. 9
National Cancer Institute (NCI) 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 17
Other 16
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Colorcon
Dow
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.